Alkermes plc. Cost of Revenue
Alkermes plc. (ALKS) reported Cost of Revenue of $98.11 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-28.
Financial Statements › Expense Statement
us-gaap:CostOfGoodsAndServicesSold · last filed 2026-07-28
- Alkermes plc. cost of goods and services sold for the quarter ending 2026-06-30 was $98.11M, a 98.37% increase year-over-year.
- Alkermes plc. cost of goods and services sold for the quarter ending 2026-03-31 was $61.58M, a 25.17% increase year-over-year.
- Alkermes plc. cost of goods and services sold for the quarter ending 2025-12-31 was $46.21M, a 25.61% decline year-over-year.
- Alkermes plc. cost of goods and services sold for the quarter ending 2025-09-30 was $51.59M, a 18.24% decline year-over-year.
- Alkermes plc. cost of goods and services sold for fiscal 2025 was $196.46M, a 19.92% decline from fiscal 2024.
- Alkermes plc. cost of goods and services sold for fiscal 2024 was $245.33M, a 3.05% decline from fiscal 2023.
- Alkermes plc. cost of goods and services sold for fiscal 2023 was $253.04M, a 16.04% increase from fiscal 2022.
- Alkermes plc. cost of goods and services sold for fiscal 2022 was $218.07M, a 10.51% increase from fiscal 2021.
| Period end | Cost of Goods and Services Sold 3 month | Cost of Goods and Services Sold 3 month as first filed | Cost of Goods and Services Sold 6 month | Cost of Goods and Services Sold 6 month as first filed | Cost of Goods and Services Sold 9 month | Cost of Goods and Services Sold 9 month as first filed | Cost of Goods and Services Sold 12 month | Cost of Goods and Services Sold 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $98.11M 10-Q · filed 2026-07-28 | $159.69M 10-Q · filed 2026-07-28 | $205.90M derived: sum of 3 quarters · filed 2026-07-28 | $257.49M derived: sum of 4 quarters · filed 2026-07-28 | ||||
| 2026-03-31 | $61.58M 10-Q · filed 2026-05-05 | $107.79M derived: sum of 2 quarters · filed 2026-05-05 | $159.38M derived: sum of 3 quarters · filed 2026-05-05 | $208.84M derived: sum of 4 quarters · filed 2026-07-28 | ||||
| 2025-12-31 | $46.21M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $97.80M derived: sum of 2 quarters · filed 2026-02-25 | $147.26M derived: sum of 3 quarters · filed 2026-07-28 | $196.46M 10-K · filed 2026-02-25 | ||||
| 2025-09-30 | $51.59M 10-Q · filed 2025-10-28 | $101.05M derived: sum of 2 quarters · filed 2026-07-28 | $150.25M 10-Q · filed 2025-10-28 | $212.36M derived: sum of 4 quarters · filed 2026-07-28 | ||||
| 2025-06-30 | $49.46M 10-Q · filed 2026-07-28 | $98.66M 10-Q · filed 2026-07-28 | $160.77M derived: sum of 3 quarters · filed 2026-07-28 | $223.87M derived: sum of 4 quarters · filed 2026-07-28 | ||||
| 2025-03-31 | $49.20M 10-Q · filed 2026-05-05 | $111.31M derived: sum of 2 quarters · filed 2026-05-05 | $174.41M derived: sum of 3 quarters · filed 2026-05-05 | $235.88M derived: sum of 4 quarters · filed 2026-05-05 | ||||
| 2024-12-31 | $62.12M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $125.22M derived: sum of 2 quarters · filed 2026-02-25 | $186.69M derived: sum of 3 quarters · filed 2026-02-25 | $245.33M 10-K · filed 2026-02-25 | ||||
| 2024-09-30 | $63.10M 10-Q · filed 2025-10-28 | $124.57M derived: sum of 2 quarters · filed 2025-10-28 | $183.22M 10-Q · filed 2025-10-28 | $253.34M derived: sum of 4 quarters · filed 2026-02-25 | ||||
| 2024-06-30 | $61.47M 10-Q · filed 2025-07-29 | $120.12M 10-Q · filed 2025-07-29 | $190.24M derived: sum of 3 quarters · filed 2026-02-25 | $251.74M derived: sum of 4 quarters · filed 2026-02-25 | ||||
| 2024-03-31 | $58.64M 10-Q · filed 2025-05-01 | $128.77M derived: sum of 2 quarters · filed 2026-02-25 | $190.27M derived: sum of 3 quarters · filed 2026-02-25 | $253.52M derived: sum of 4 quarters · filed 2026-02-25 | ||||
| 2023-12-31 | $70.13M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $131.62M derived: sum of 2 quarters · filed 2026-02-25 | $194.87M derived: sum of 3 quarters · filed 2026-02-25 | $253.04M 10-K · filed 2026-02-25 | ||||
| 2023-09-30 | $61.50M 10-Q · filed 2024-10-24 | $61.51M 10-Q · filed 2023-10-25 | $124.75M derived: sum of 2 quarters · filed 2024-10-24 | $182.91M 10-Q · filed 2024-10-24 | $182.94M 10-Q · filed 2023-10-25 | $236.84M derived: sum of 4 quarters · filed 2025-02-12 | ||
| 2023-06-30 | $63.25M 10-Q · filed 2024-07-24 | $63.26M 10-Q · filed 2023-07-26 | $121.41M 10-Q · filed 2024-07-24 | $121.44M 10-Q · filed 2023-07-26 | $175.34M derived: sum of 3 quarters · filed 2025-02-12 | $225.96M derived: sum of 4 quarters · filed 2025-02-12 | ||
| 2023-03-31 | $58.16M 10-Q · filed 2024-05-01 | $58.17M 10-Q · filed 2023-04-26 | $112.09M derived: sum of 2 quarters · filed 2025-02-12 | $162.71M derived: sum of 3 quarters · filed 2025-02-12 | $221.07M derived: sum of 4 quarters · filed 2025-02-12 | |||
| 2022-12-31 | $53.92M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-12 | $104.55M derived: sum of 2 quarters · filed 2025-02-12 | $162.91M derived: sum of 3 quarters · filed 2025-02-12 | $218.07M 10-K · filed 2025-02-12 | $218.11M 10-K · filed 2023-02-16 | |||
| 2022-09-30 | $50.63M 10-Q · filed 2023-10-25 | $108.98M derived: sum of 2 quarters · filed 2023-10-25 | $164.14M 10-Q · filed 2023-10-25 | $217.76M derived: sum of 4 quarters · filed 2024-02-21 | ||||
| 2022-06-30 | $58.36M 10-Q · filed 2023-07-26 | $113.52M 10-Q · filed 2023-07-26 | $167.14M derived: sum of 3 quarters · filed 2024-02-21 | $216.70M derived: sum of 4 quarters · filed 2024-02-21 | ||||
| 2022-03-31 | $55.16M 10-Q · filed 2023-04-26 | $108.78M derived: sum of 2 quarters · filed 2024-02-21 | $158.34M derived: sum of 3 quarters · filed 2024-02-21 | $211.46M derived: sum of 4 quarters · filed 2024-02-21 | ||||
| 2021-12-31 | $53.62M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-21 | $103.18M derived: sum of 2 quarters · filed 2024-02-21 | $156.30M derived: sum of 3 quarters · filed 2024-02-21 | $197.32M 10-K · filed 2024-02-21 | $197.39M 10-K · filed 2022-02-16 | |||
| 2021-09-30 | $49.56M 10-Q · filed 2022-11-02 | $102.69M derived: sum of 2 quarters · filed 2022-11-02 | $143.71M 10-Q · filed 2022-11-02 | $186.63M derived: sum of 4 quarters · filed 2023-02-16 | ||||
| 2021-06-30 | $53.12M 10-Q · filed 2022-07-27 | $94.14M 10-Q · filed 2022-07-27 | $137.07M derived: sum of 3 quarters · filed 2023-02-16 | $180.19M derived: sum of 4 quarters · filed 2023-02-16 | ||||
| 2021-03-31 | $41.02M 10-Q · filed 2022-04-27 | $83.94M derived: sum of 2 quarters · filed 2023-02-16 | $127.07M derived: sum of 3 quarters · filed 2023-02-16 | $172.12M derived: sum of 4 quarters · filed 2023-02-16 | ||||
| 2020-12-31 | $42.92M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-16 | $86.05M derived: sum of 2 quarters · filed 2023-02-16 | $131.10M derived: sum of 3 quarters · filed 2023-02-16 | $178.32M 10-K · filed 2023-02-16 | ||||
| 2020-09-30 | $43.13M 10-Q · filed 2021-10-27 | $88.18M derived: sum of 2 quarters · filed 2021-10-27 | $135.39M 10-Q · filed 2021-10-27 | $181.88M derived: sum of 4 quarters · filed 2022-02-16 | ||||
| 2020-06-30 | $45.05M 10-Q · filed 2021-07-28 | $92.26M 10-Q · filed 2021-07-28 | $138.75M derived: sum of 3 quarters · filed 2022-02-16 | $181.06M derived: sum of 4 quarters · filed 2022-02-16 | ||||
| 2020-03-31 | $47.21M 10-Q · filed 2021-04-28 | $93.69M derived: sum of 2 quarters · filed 2022-02-16 | $136.01M derived: sum of 3 quarters · filed 2022-02-16 | $182.24M derived: sum of 4 quarters · filed 2022-02-16 | ||||
| 2019-12-31 | $46.48M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-16 | $88.80M derived: sum of 2 quarters · filed 2022-02-16 | $135.02M derived: sum of 3 quarters · filed 2022-02-16 | $180.38M 10-K · filed 2022-02-16 | ||||
| 2019-09-30 | $42.32M 10-Q · filed 2020-10-29 | $88.54M derived: sum of 2 quarters · filed 2020-10-29 | $133.90M 10-Q · filed 2020-10-29 | $183.02M derived: sum of 4 quarters · filed 2021-02-11 | ||||
| 2019-06-30 | $46.22M 10-Q · filed 2020-07-29 | $91.58M 10-Q · filed 2020-07-29 | $140.70M derived: sum of 3 quarters · filed 2021-02-11 | $180.11M derived: sum of 4 quarters · filed 2021-02-11 | ||||
| 2019-03-31 | $45.36M 10-Q · filed 2020-04-29 | $94.48M derived: sum of 2 quarters · filed 2021-02-11 | $133.89M derived: sum of 3 quarters · filed 2021-02-11 | $177.31M derived: sum of 4 quarters · filed 2021-02-11 | ||||
| 2018-12-31 | $49.12M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-11 | $88.53M derived: sum of 2 quarters · filed 2021-02-11 | $131.94M derived: sum of 3 quarters · filed 2021-02-11 | $176.42M 10-K · filed 2021-02-11 | ||||
| 2018-09-30 | $39.41M 10-Q · filed 2019-10-23 | $82.83M derived: sum of 2 quarters · filed 2019-10-23 | $127.30M 10-Q · filed 2019-10-23 | $165.81M derived: sum of 4 quarters · filed 2020-02-13 | ||||
| 2018-06-30 | $43.42M 10-Q · filed 2019-07-25 | $87.89M 10-Q · filed 2019-07-25 | $126.40M derived: sum of 3 quarters · filed 2020-02-13 | $162.45M derived: sum of 4 quarters · filed 2020-02-13 | ||||
| 2018-03-31 | $44.48M 10-Q · filed 2019-04-25 | $82.98M derived: sum of 2 quarters · filed 2020-02-13 | $119.04M derived: sum of 3 quarters · filed 2020-02-13 | $158.81M derived: sum of 4 quarters · filed 2020-02-13 | ||||
| 2017-12-31 | $38.51M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-13 | $74.56M derived: sum of 2 quarters · filed 2020-02-13 | $114.34M derived: sum of 3 quarters · filed 2020-02-13 | $154.75M 10-K · filed 2020-02-13 | ||||
| 2017-09-30 | $36.05M 10-Q · filed 2018-10-23 | $75.83M derived: sum of 2 quarters · filed 2018-10-23 | $116.24M 10-Q · filed 2018-10-23 | |||||
| 2017-06-30 | $39.77M 10-Q · filed 2018-07-26 | $80.19M 10-Q · filed 2018-07-26 | ||||||
| 2016-12-31 | $132.12M 10-K · filed 2019-02-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |